Find

  • All tenders
Germany: Tenders/BiconY Therapeutics GmbH/Toxicity study in naïve mice

Toxicity study in naïve mice

Awarded

The competition has ended and a winner has been selected.

Deadline
Dec 14, 2025Expired
Award
Date of final QA Report (audited), weight 50
Procedure
OpenSingle stage
Agreement
Buying servicesuntil May 2026

Brief

The Federal Agency for Disruptive Innovation - SPRIND GmbH ("SPRIND") - aims to cre-ate new disruptive innovations from Germany. That means products, services and sys-tems that make all our lives noticeably and sustainably better. To achieve this, SPRIND brings together new thinkers from science and business, people with outstanding ideas, special expertise, and passion. Hence, SPRIND provides an entrepreneurial environment that turns ideas into reality. The objective of BiconY Therapeutics GmbH, a SPRIND subsidiary, is the development of a bispecific antibody combination for the treatment of solid tumours. The combination con-sists of proprietary, bispecific CD3 anti-bodies (bsAbCD3) and bispecific CD28 co-stimulators (BiCos), which, when used together, significantly im-prove the specificity, sus-tainability, and efficiency of a T cell recruitment and thus the immune response against tumour cells. The aim of the research and development activities is to provide proof of concept for the effect of bispecific antibody therapy in the form of two phase I/IIa clinical trials. For the IND application at Paul Ehrlich Institute (Germany) we have to show safety of our molecules in animal models. Following extensive discussions and thorough analyses, the PEI has granted approval for a comprehensive toxicological study of our lead candidate in mice. Therefore, we are looking for a service provider to support us regarding pharmaco-toxicological studies

Result

TED
  • vivo Science GmbH
    Winner
  • Number of tenders received
    3
  • Contract value
    -€1

Previous winners

  • Who are you up against?

    The suppliers who have won similar contracts at BiconY Therapeutics GmbH

Will you bid?

The agent sets up the bid and writes the first draft. Free for 14 days.

Award Criteria

  • Description

    The award criterion price will be evaluated as follows: The lowest bid price according to the Price sheet (Form for offer) will be awarded the highest number of points (5). The number of points for the prices offered will be determined as follows: Points of the bidder = lowest price x 5 / bidder's offered price The score achieved is rounded to two decimal places.

    Source

    No source found in the documents. Check the weight against the tender documents.

  • Description

    The award criterion Date of final QA Report (audited) will be evaluated as follows: Date Points Till March 27, 2026 5 Till April 3, 2026 4 Till April 11, 2026 3 Till April 18, 2026 2 Till April 25, 2026 1 Till May 29, 2026 0 Please note: 29 May 2026 is the latest possible date A total of up to 10 points can be achieved (5 price points and 5 timeline points for final QA report audited).

    Source

    No source found in the documents. Check the weight against the tender documents.

From the notice

  • The Federal Agency for Disruptive Innovation - SPRIND GmbH ("SPRIND") - aims to cre-ate new disruptive innovations from Germany. That means products, services and sys-tems that make all our lives noticeably and sustainably better. To achieve this, SPRIND brings together new thinkers from science and business, people with outstanding ideas, special expertise, and passion. Hence, SPRIND provides an entrepreneurial environment that turns ideas into reality. The objective of BiconY Therapeutics GmbH, a SPRIND subsidiary, is the development of a bispecific antibody combination for the treatment of solid tumours. The combination con-sists of proprietary, bispecific CD3 anti-bodies (bsAbCD3) and bispecific CD28 co-stimulators (BiCos), which, when used together, significantly im-prove the specificity, sus-tainability, and efficiency of a T cell recruitment and thus the immune response against tumour cells. The aim of the research and development activities is to provide proof of concept for the effect of bispecific antibody therapy in the form of two phase I/IIa clinical trials. For the IND application at Paul Ehrlich Institute (Germany) we have to show safety of our molecules in animal models. Following extensive discussions and thorough analyses, the PEI has granted approval for a comprehensive toxicological study of our lead candidate in mice. Therefore, we are looking for a service provider to support us regarding pharmaco-toxicological studies

  • Contact

    bicony.tenderprocedure@fgvw.de
  • Type
    Result
  • Main code
    Research and development services and related consultancy services
    73000000

Similar active competitions

  • Helmholtz-Zentrum für Infektionsforschung GmbH

    Forsknings- og utviklingsvirksomhet og tilhørende konsulenttjenester

    Non-Clinical Toxicology and safety assessment of a small molecule

    Helmholtz-Zentrum für Infektionsforschung GmbH seeks services under a framework agreement to conduct a nonclinical toxicology and safety assessment programme for a small-molecule drug candidate, with delivery in Braunschweig, Germany. The work includes assessing safety after intravenous infusion, with particular focus on renal function and toxicity, and a dermal toxicology programme to support a potential topical semisolid formulation; the dermal work is subject to a Go/No-Go decision. The programme must meet applicable regulatory requirements and produce documentation suitable for submissions in the EU and US, supporting first-in-human trials and further clinical development. The project manager must have C1-level German or English, and applicable studies must comply with OECD GLP or equivalent principles, supported by GLP compliance evidence. Evaluation gives 75% weight to quality (project execution concept 45%, capability concept 30%) and 25% to price.

    Framework agreement
    Dec 7, 2026(15 days)